Comprehensive Analysis of the Peptide Based Metabolic Disorders Therapeutics Market 2025-2034: Growth Rates, Trends, and Future Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the peptide based metabolic disorders therapeutics market grown in recent years?
The therapeutic market size for peptide-based metabolic disorders has seen a swift growth in the past few years. The value of the market is projected to rise from $29.89 billion in 2024 to $34.4 billion in 2025, indicating a compound annual growth rate (CAGR) of 15.1%. This growth during the historic period can be traced back to factors such as the rising occurrence of metabolic disorders, advancements in peptide synthesis technologies, higher healthcare spending, growth in the aging population, an expanding biopharmaceutical sector, approval of new therapeutic methods by regulatory bodies, and growing awareness regarding personalized medicine.
How is the peptide based metabolic disorders therapeutics market size expected to evolve during the forecast period?
The market size for peptide-based metabolic disorder therapeutics is projected to expand significantly in the coming years, reaching a value of $59.85 billion in 2029, with a compound annual growth rate (CAGR) of 14.8%. Factors influencing this heightened growth during the projection period include innovation in peptide analogs, increased R&D investments in metabolic disorders, acceptance of precision medicine strategies, growth in developing markets, cooperation, and drug development partnerships, enhancements in delivery technologies, along with a shift towards patient-focused treatments. Key market trends anticipated during this period include the employment of artificial intelligence in drug discovery, the rise in tailor-made therapies, use of CRISPR/Cas9 for gene therapies, the incorporation of wearable patient monitoring devices, advancements in oral peptide formulations, the rise of digital therapeutics in disease management, along with an increase in biobanking for customized treatments.
Get your peptide based metabolic disorders therapeutics market report here!
Which key drivers are propelling the peptide based metabolic disorders therapeutics market’s growth?
The escalating incidence of obesity is anticipated to fuel the peptide-based metabolic disorders therapeutic market’s expansion in the future. Obesity, typically marked by an excessive accumulation of body fat, poses severe health risks. The rise in obesity cases can be attributed to factors such as sedentary lifestyles, poor eating habits, genetics, and environment that encourage consumption of high-calorie foods and physical inactivity. Peptide-based therapies for metabolic disorders are designed to manage conditions like obesity by utilizing peptides to control metabolic functions, enhance insulin sensitivity, and regulate appetite, ultimately improving patients’ health and minimizing the long-term health risks linked to these chronic disorders. For instance, The British Diabetic Association reported in April 2024 that 4.4 million people in the UK are living with diabetes, while an additional estimated 1.2 million may have undiagnosed type 2 diabetes. The registration figures for 2022-23 have risen by 167,822 compared to 2021-22. Therefore, the increasing incidence of obesity is stimulating the growth of the peptide-based metabolic disorder therapeutics market.
What are the market segments in the peptide based metabolic disorders therapeutics industry?
The peptide based metabolic disorders therapeutics market covered in this report is segmented –
1) By Drug Type: Liraglutide, Exenatide, Other Drug Type
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity
2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide
3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp
Which leading companies are shaping the growth of the peptide based metabolic disorders therapeutics market?
Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group
What emerging trends are influencing the growth of the peptide based metabolic disorders therapeutics market?
Leading firms in the peptide-based metabolic disorders therapeutics market are focusing on creating novel peptide-based therapies, including anti-diabetic biosimilars, that can fulfill unmet medical requirements and widen the range of treatment choices for patients. These anti-diabetic biosimilars are therapeutic medicines that replicate existing peptide-based treatments for diabetes, delivering similar safety and effectiveness as established drugs but potentially at a lower cost due to competitive price strategies. For example, Glenmark Pharmaceuticals Ltd., a pharmaceutical entity from India, introduced Lirafit, a biosimilar variant of the well-known anti-diabetic medication Liraglutide, in India in January 2024. Lirafit falls under the category of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), drugs that emulate the function of the naturally occurring GLP-1 hormone key in controlling blood sugar levels. Clinical trials have shown that this biosimilar successfully reduces glycemic indicators, encourages weight loss, and enhances cardiovascular safety. These are vital elements in managing diabetes and related conditions like obesity and cardiovascular diseases.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16764
Which geographic areas are influencing the growth of the peptide based metabolic disorders therapeutics market?
North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Digital Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report
Medical Foods Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market
Home Insurance Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/ultrasound-devices-and-equipment-market
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
